31004-60-1

Upstream product

• 31004-53-2 1.1-Dimethoxy-3-phenyl-3-cyan-butan 
• 30932-04-8 4,4-Diaethoxy-2-phenyl-2-methyl-butyronitril 
• 123064-05-1 3-cyano-3-methyl-3-phenylpropanoic acid ethyl ester 

Downstream Products

• 103797-72-4 4-hydroxy-2-methyl-2-phenyl-butirronitrile 
• 869381-65-7 C₁₉H₂₂N₂ 
• 1262786-67-3 2-methyl-4-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenyl-1-butanamine 
• 1262786-72-0 (2-methyl-4-{(1R,5S)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-2-phenylbutyl)amine 
• 1262786-44-6 N-methyl-N-{2-methyl-4-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutyl}benzenesulfonamide 
• 1262786-43-5 N-{2-methyl-4-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutyl}benzenesulfonamide 
• 1262786-50-4 N-(2-methyl-4-{(1R,5S)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-2-phenylbutyl)benzenesulfonamide 
• 1262786-46-8 C₃₄H₄₄F₂N₄O 
• 1262786-45-7 4,4-difluoro-N-{2-methyl-4-[(1R,5S)-3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutyl}cyclohexanecarboxamide 
• 1262786-48-0 4,4-difluoro-N-(2-methyl-4-{(1R,5S)-3-[3-methyl-5-(1-methylethyl)-4H-1,2,4-triazol-4-yl]-8-azabicyclo[3.2.1]oct-8-yl}-2-phenylbutyl)cyclohexanecarboxamide 
• 869381-67-9 BrH*C₁₉H₂₃NO₂ 
• 869381-66-8 C₁₉H₂₄N₂O 
• 1262786-66-2 2-methyl-4-[3-(2-methyl-1H-benzimidazol-1-yl)-8-azabicyclo[3.2.1]oct-8-yl]-2-phenylbutanenitrile 
• 1282658-40-5 C₂₄H₃₃N₅ 

Relevant academic research and scientific papers

Synthesis and evaluation of 2-phenyl-1,4-butanediamine-based CCR5 antagonists for the treatment of HIV-1

We describe the synthesis and potency of a novel series of N-substituted 2-phenyl- and 2-methyl-2-phenyl-1,4-diaminobutane- based CCR5 antagonists. Compounds 7a and 12f were found to be potent in anti-HIV assays and bioavailable in the low-dose rat PK model.

THERAPEUTIC COMPOUNDS

The present invention relates to compounds of Formula (I) and (Ia) useful in the treatment of CCR5-related diseases and disorders, for example, the prevention or treatment of an HIV infection, and in the treatment of the resulting acquired immune deficien

ADAMANTYL PYRROLIDIN-2-ONE DERIVATIVES AS 11-BETA HYDROXYSTEROID DEHYDROGENASE INHIBITORS

The N-oxide forms, the pharmaceutically acceptable addition salts and the stereochemically isomeric forms thereof, wherein n is 1 or 2; M represents a direct bond or a C1-3alkyl linker optionally substituted with one or two substituents selected from C1-4